MAP2K2 and non-small cell lung carcinoma: MEK1 and MEK2 were known as downstream components of KRAS/RAF signaling pathway, and current studies have shown they were potential therapeutic targets for NSCLC and specific inhibitor, Trametinib has been developed and exhibited promising effects in clinical trials [13–15].